Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer
Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer
复制标题
芳香酶抑制剂与节拍卡培他滨的组合：晚期乳腺癌的新化学内分泌治疗
DOI：
--
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Zhongyu Yuan
中科院分区：
文献类型：
--
作者：
W. Shi;Xinyue Wang;X. Bi;W. Xia;Jiajia Huang;Yanhong Su;Zhangzan Huang;Zhongyu Yuan
目的：内分泌治疗是激素受体（HR）阳性晚期乳腺癌（ABC）的主要治疗选择之一。然而，内分泌治疗联合化疗是否可行，是否比单纯内分泌治疗更有效，仍是未知数。本研究旨在探讨芳香化酶抑制剂（AIs）联合卡培他滨节拍治疗HR阳性ABC患者的临床疗效，为进一步研究提供临床依据。方法：回顾性分析407例HR阳性ABC患者的临床资料。共有305例患者接受了AI单药治疗，102例患者接受了AI+卡培他滨一线治疗。无进展生存期（PFS）是主要终点。结果：所有患者的中位随访时间为47.0个月（范围，3 - 119个月）。中位总生存期（OS）和PFS分别为52.0个月和24.2个月。联合治疗组的中位PFS显著长于AI组（22.0个月vs. 14.0个月，p = 0.002）。此外，联合治疗组患者的OS显著长于AI组患者（66.0个月vs. 49.0个月，p = 0.003）。多变量分析显示，联合治疗是PFS和OS的显著有利预测因素。此外，年轻（24个月）可改善联合治疗的获益。结论：AI联合节拍卡培他滨显著改善HR阳性ABC患者的PFS和OS。因此，化学内分泌治疗应进一步探索。
Purpose: Endocrine therapy is one of the main treatment options for hormone receptor (HR)-positive advanced breast cancer (ABC). However, whether the combination of endocrine therapy with chemotherapy is practicable and more effective than endocrine therapy alone remains unknown. The aim of this study was to investigate the clinical efficacy of the aromatase inhibitors (AIs) combined with metronomic capecitabine to provide the clinical evidence for further research in patients with HR-positive ABC. Methods: Data from 407 patients with HR-positive ABC were retrospectively analyzed. A total of 305 patients were given AIs alone, and 102 patients were given AIs plus capecitabine as first-line treatment. Progression-free survival (PFS) was the primary endpoint. Results: The median follow-up for all patients was 47.0 months (range, 3 - 119 months). The median overall survival (OS) and PFS were 52.0 months and 24.2 months, respectively. The median PFS in the combination group was significantly longer than that in the AIs group (22.0 months vs. 14.0 months, p = 0.002). Additionally, patients in the combination group had significantly longer OS than patients in the AI group (66.0 months vs. 49.0 months, p = 0.003). Multivariate analysis showed that combination therapy was a significant favorable predictor for PFS and OS. Furthermore, young age ( 24 months) improved the benefit from combination therapy. Conclusions: AIs plus metronomic capecitabine significantly improves PFS and OS in patients with HR-positive ABC. Thus, chemo-endocrine therapy should be further explored.
影响因子：
45.3
作者：
Paridaens, Robert J.;Dirix, Luc Y.;Therasse, Patrick
通讯作者：
Therasse, Patrick
影响因子：
45.3
作者：
Anders, Carey K.;Hsu, David S.;Blackwell, Kimberly L.
通讯作者：
Blackwell, Kimberly L.
影响因子：
45.3
作者：
OSBORNE, CK;KITTEN, L;ARTEAGA, CL
通讯作者：
ARTEAGA, CL